Related Experiment Video
Updated: Jun 17, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Effect of second-generation antipsychotics on cognition: current issues and future challenges
S Kristian Hill1, Jeffrey R Bishop, Donna Palumbo
1Center for Cognitive Medicine (M/C 913), University of Illinois at Chicago, 912 South Wood Street, Suite 235, Chicago, IL 60612, USA. shill@psych.uic.edu
Abstract:
Generalized cognitive impairments are stable deficits linked to schizophrenia and key factors associated with functional disability in the disorder. Preclinical data suggest that second-generation antipsychotics could potentially reduce cognitive impairments; however, recent large clinical trials indicate only modest cognitive benefits relative to first-generation antipsychotics. This might reflect a limited drug effect in humans, a differential drug effect due to brain alterations associated with schizophrenia, or limited sensitivity of the neuropsychological tests for evaluating cognitive outcomes. New adjunctive procognitive drugs may be needed to achieve robust cognitive and functional improvement. Drug discovery may benefit from greater utilization of translational neurocognitive biomarkers to bridge preclinical and clinical proof-of-concept studies, to optimize assay sensitivity, enhance cost efficiency, and speed progress in drug development.
Related Concept Videos
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Drug Therapy
Antianxiety Medications
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists